Addendum

Fezolinetant (vasomotor symptoms in menopause) – Addendum to Project A24-15

Report documents

Indication:

Menopausal women with moderate to severe vasomotor symptoms

Result of dossier assessment:

Patients for whom hormone therapy is an option and who have decided in favour of hormone replacement therapy after an individual risk-benefit assessment: added benefit not proven
Patients for whom hormone therapy is not an option or those who have decided against therapy after an individual risk-benefit assessment: hint of considerable added benefit

2024-08-01 A G-BA decision was published.

Project no.: A24-69
Commission: Commission awarded on 11.06.2024 by the Federal Joint Committee (GBA).
Report type: Addendum
Status: Commission completed
Department/Division: Drug Assessment
Topic: Reproductive health and birth
Note: If the need for additional work on a project commissioned by the GBA arises during consultations, IQWiG submits an addendum. The subsequent decides on the extent of the added benefit concludes the early benefit assessment.
DOI: https://doi.org/10.60584/A24-69_en

Press contact

+49 221 356850

press@iqwig.de

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.